US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine candidate showed 89.3 per cent efficacy in a major phase 3 clinical trial in Britain.But the positive news was offset by results that showed it was much less effective against a highly transmissible variant of the coronavirus first identified in South Africa that is spreading quickly around the world.The company said it would immediately begin developing a new vaccine targeting this variant.“NVX-CoV2373 has the potential to…

Read More